Abstract
Following myocardial infarction (MI), maladaptive upregulation of matrix metalloproteinase (MMP) alters extracellular matrix leading to cardiac remodeling. Intramyocardial hydrogel delivery provides a vehicle for local delivery of MMP tissue inhibitors (rTIMP-3) for MMP activity modulation. We evaluated swine 10–14 days following MI randomized to intramyocardial delivery of saline, degradable hyaluronic acid (HA) hydrogel, or rTIMP-3 releasing hydrogel with an MMP-targeted radiotracer (99mTc-RP805), 201Tl, and CT. Significant left ventricle (LV) wall thinning, increased wall stress, reduced circumferential wall strain occurred in the MI region of MI-Saline group along with left atrial (LA) dilation, while these changes were modulated in both hydrogel groups. 99mTc-RP805 activity increased twofold in MI-Saline group and attenuated in hydrogel animals. Infarct size significantly reduced only in rTIMP-3 hydrogel group. Hybrid SPECT/CT imaging demonstrated a therapeutic benefit of intramyocardial delivery of hydrogels post-MI and reduced remodeling of LA and LV in association with a reduction in MMP activation.
Graphical abstract
Similar content being viewed by others
References
Dixon, J. A., & Spinale, F. G. (2011). Myocardial remodeling: Cellular and extracellular events and targets. Annual Review of Physiology, 73, 47–68.
Beinart, R., Boyko, V., Schwammenthal, E., Kuperstein, R., Sagie, A., Hod, H., et al. (2004). Long-term prognostic significance of left atrial volume in acute myocardial infarction. Journal of the American College of Cardiology, 44, 327–334.
Stacy, M. R., Lin, B. A., Thorn, S. L., Lobb, D. C., Maxfield, M. W., Novack, C., et al. (2022). Regional heterogeneity in determinants of atrial matrix remodeling and association with atrial fibrillation vulnerability postmyocardial infarction. Heart Rhythm, 19, 847–855.
Lindsey, M. L., Iyer, R. P., Jung, M., DeLeon-Pennell, K. Y., & Ma, Y. (2016). Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling. Journal of Molecular and Cellular Cardiology, 91, 134–140.
Thorn, S. L., Barlow, S. C., Feher, A., Stacy, M. R., Doviak, H., Jacobs, J., et al. (2019). Application of hybrid matrix metalloproteinase-targeted and dynamic (201)Tl single-photon emission computed tomography/computed tomography imaging for evaluation of early post-myocardial infarction remodeling. Circulation: Cardiovascular Imaging, 12, e009055.
Su, H., Spinale, F. G., Dobrucki, L. W., Song, J., Hua, J., Sweterlitsch, S., et al. (2005). Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation, 112, 3157–3167.
Sahul, Z. H., Mukherjee, R., Song, J., McAteer, J., Stroud, R. E., Dione, D. P., et al. (2011). Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: Relationship to myocardial dysfunction. Circulation: Cardiovascular Imaging, 4, 381–91.
Spinale, F. G., Coker, M. L., Heung, L. J., Bond, B. R., Gunasinghe, H. R., Etoh, T., et al. (2000). A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation, 102, 1944–1949.
Morishita, T., Uzui, H., Mitsuke, Y., Amaya, N., Kaseno, K., Ishida, K., et al. (2017). Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure. ESC Heart Failure, 4, 321–330.
Li, Y. Y., Feldman, A. M., Sun, Y., & McTiernan, C. F. (1998). Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation, 98, 1728–1734.
Apple, K. A., Yarbrough, W. M., Mukherjee, R., Deschamps, A. M., Escobar, P. G., Mingoia, J. T., et al. (2006). Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. Journal of Cardiovascular Pharmacology, 47, 228–235.
Purcell, B. P., Lobb, D., Charati, M. B., Dorsey, S. M., Wade, R. J., Zellars, K. N., et al. (2014). Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nature Materials, 13, 653–661.
Cerisano, G., Buonamici, P., Gori, A. M., Valenti, R., Sciagra, R., Giusti, B., et al. (2015). Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial. International Journal of Cardiology, 197, 147–53.
Hudson, M. P., Armstrong, P. W., Ruzyllo, W., Brum, J., Cusmano, L., Krzeski, P., et al. (2006). Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. Journal of the American College of Cardiology, 48, 15–20.
Tous, E., Ifkovits, J. L., Koomalsingh, K. J., Shuto, T., Soeda, T., Kondo, N., et al. (2011). Influence of injectable hyaluronic acid hydrogel degradation behavior on infarction-induced ventricular remodeling. Biomacromolecules, 12, 4127–4135.
Mukherjee, R., Zavadzkas, J. A., Saunders, S. M., McLean, J. E., Jeffords, L. B., Beck, C., et al. (2008). Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Annals of Thoracic Surgery, 86, 1268–1276.
McLaughlin, S., McNeill, B., Podrebarac, J., Hosoyama, K., Sedlakova, V., Cron, G., et al. (2019). Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction. Nature Communications, 10, 4866.
Rodell, C. B., Lee, M. E., Wang, H., Takebayashi, S., Takayama, T., Kawamura, T., Arkles J. S., Dusaj, N. N., Dorsey, S. M., Witschey, W. R., Pilla, J. J., Gorman, J. H. 3rd, Wenk, J. F., Burdick, J. A., & Gorman, R. C. (2016). Injectable shear-thinning hydrogels for minimally invasive delivery to infarcted myocardium to limit left ventricular remodeling. Circulation: Cardiovascular Interventions, 9(10):e004058. https://doi.org/10.1161/CIRCINTERVENTIONS.116.004058
Tous, E., Purcell, B., Ifkovits, J. L., & Burdick, J. A. (2011). Injectable acellular hydrogels for cardiac repair. Journal of Cardiovascular Translational Research, 4, 528–542.
Chen, M. H., Chung, J. J., Mealy, J. E., Zaman, S., Li, E. C., Arisi, M. F., et al. (2019). Injectable supramolecular hydrogel/microgel composites for therapeutic delivery. Macromolecular Bioscience, 19, e1800248.
Wang, L. L., Chung, J. J., Li, E. C., Uman, S., Atluri, P., & Burdick, J. A. (2018). Injectable and protease-degradable hydrogel for siRNA sequestration and triggered delivery to the heart. Journal of Controlled Release, 285, 152–161.
Purcell, B. P., Barlow, S. C., Perreault, P. E., Freeburg, L., Doviak, H., Jacobs, J., et al. (2018). Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling. American Journal of Physiology: Heart and Circulatory Physiology, 315, H814–H825.
Wang, H., Rodell, C. B., Zhang, X., Dusaj, N. N., Gorman, J. H., 3rd., Pilla, J. J., et al. (2018). Effects of hydrogel injection on borderzone contractility post-myocardial infarction. Biomechanics and Modeling in Mechanobiology, 17, 1533–1542.
Wang, L. L., Liu, Y., Chung, J. J., Wang, T., Gaffey, A. C., Lu, M., et al. (2017). Local and sustained miRNA delivery from an injectable hydrogel promotes cardiomyocyte proliferation and functional regeneration after ischemic injury. Nature Biomedical Engineering, 1, 983–992.
Eckhouse, S. R., Purcell, B. P., McGarvey, J. R., Lobb, D., Logdon, C. B., Doviak, H., et al. (2014). Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Science Translational Medicine, 6, 223ra21.
Lobb, D. C., Doviak, H., Brower, G. L., Romito, E., O’Neill, J. W., Smith, S., et al. (2020). Targeted injection of a truncated form of tissue inhibitor of metalloproteinase 3 alters post-myocardial infarction remodeling. Journal of Pharmacology and Experimental Therapeutics, 375, 296–307.
Liu, Y. H., Sahul, Z., Weyman, C. A., Dione, D. P., Dobrucki, W. L., Mekkaoui, C., et al. (2011). Accuracy and reproducibility of absolute quantification of myocardial focal tracer uptake from molecularly targeted SPECT/CT: A canine validation. Journal of Nuclear Medicine, 52, 453–460.
Torres, W. M., Jacobs, J., Doviak, H., Barlow, S. C., Zile, M. R., Shazly, T., et al. (2018). Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. American Journal of Physiology: Heart and Circulatory Physiology, 315, H958–H967.
Shehata, I. E., Cheng, C. I., Sung, P. H., Ammar, A. S., El-Sherbiny, I. A. E., & Ghanem, I. G. A. (2018). Predictors of myocardial functional recovery following successful reperfusion of acute ST elevation myocardial infarction. Echocardiography, 35, 1571–1578.
Spinale, F. G., Mukherjee, R., Zavadzkas, J. A., Koval, C. N., Bouges, S., Stroud, R. E., et al. (2010). Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. Journal of Biological Chemistry, 285, 30316–30327.
Iyer, R. P., Jung, M., & Lindsey, M. L. (2016). MMP-9 signaling in the left ventricle following myocardial infarction. American Journal of Physiology: Heart and Circulatory Physiology, 311, H190–H198.
Takawale, A., Zhang, P., Azad, A., Wang, W., Wang, X., Murray, A. G., et al. (2017). Myocardial overexpression of TIMP3 after myocardial infarction exerts beneficial effects by promoting angiogenesis and suppressing early proteolysis. American Journal of Physiology: Heart and Circulatory Physiology, 313, H224–H236.
Yan, A. T., Yan, R. T., Spinale, F. G., Afzal, R., Gunasinghe, H. R., Stroud, R. E., et al. (2008). Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. European Journal of Heart Failure, 10, 125–128.
Kondo, N., Temma, T., Aita, K., Shimochi, S., Koshino, K., Senda, M., et al. (2018). Development of matrix metalloproteinase-targeted probes for lung inflammation detection with positron emission tomography. Sci Rep-Uk, 8, 1347–1357.
Acknowledgements
We would like to acknowledge the assistance of the University of South Carolina and Yale University veterinarian staff for their assistance with ensuring the health and well-being of the animals in this study. We also acknowledge the technical assistance of Christi Hawley.
Funding
This work was supported by the National Institute of Health grants: R01HL113352 (AJS), R01HL137365 (AJS), T32HL098069 (AJS), S10RR025555 (AJS), and R42HL131280 (FGS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics Approval and Consent to Participate
No human studies were carried out by the authors for this article. All institutional and national guidelines for the care and use of laboratory animals were followed and approved by the appropriate institutional committees at the University of South Carolina and Yale University.
Conflict of Interest
F.G. Spinale is the founder of MicroVide, LLC, and A.J. Sinusas is a limited partner and consultant of MicroVide, LLC, which holds the license for the use of 99mTc-RP805 in myocardial applications.
Additional information
Associate Editor Craig M. Stolen oversaw the review of this article
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Thorn, S.L., Shuman, J.A., Stacy, M.R. et al. Matrix Metalloproteinase-Targeted SPECT/CT Imaging for Evaluation of Therapeutic Hydrogels for the Early Modulation of Post-Infarct Myocardial Remodeling. J. of Cardiovasc. Trans. Res. 16, 155–165 (2023). https://doi.org/10.1007/s12265-022-10280-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-022-10280-7